0001209191-19-002668.txt : 20190107
0001209191-19-002668.hdr.sgml : 20190107
20190107203346
ACCESSION NUMBER: 0001209191-19-002668
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190103
FILED AS OF DATE: 20190107
DATE AS OF CHANGE: 20190107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brady Stephen R
CENTRAL INDEX KEY: 0001606241
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36561
FILM NUMBER: 19514524
MAIL ADDRESS:
STREET 1: C/O IMMUNE DESIGN CORP.
STREET 2: 1616 EASTLAKE AVE. E, SUITE 310
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNE DESIGN CORP.
CENTRAL INDEX KEY: 0001437786
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262007174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1616 EASTLAKE AVENUE E.
STREET 2: SUITE 310
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: (650) 392-8350
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 250
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Immune Design Corp.
DATE OF NAME CHANGE: 20090702
FORMER COMPANY:
FORMER CONFORMED NAME: VACCSYS INC
DATE OF NAME CHANGE: 20080617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-03
0
0001437786
IMMUNE DESIGN CORP.
IMDZ
0001606241
Brady Stephen R
C/O IMMUNE DESIGN CORP.
1616 EASTLAKE AVE. E., SUITE 310
SEATTLE
WA
98102
0
1
0
0
EVP, Strategy & Finance
Common Stock
2019-01-03
4
A
0
25000
0.00
A
102115
D
Common Stock
2019-01-07
4
S
0
5516
1.5812
D
96599
D
Stock Option (right to buy)
1.31
2019-01-03
4
A
0
120000
0.00
A
2029-01-03
Common Stock
120000
120000
D
Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date.
The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016, January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.62 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date.
/s/ Stephen R. Brady
2019-01-07